Table 4.

Grade ≥ 3 treatment-emergent adverse events of three subgroups with different regimens inpatients with unresectable pancreatic cancer.

	Nab-Paclitaxel Plus Gem	mFOLFIRINOX	GEMOX
Patients assessed (n)	56	25	22
Total grade ≥ 3 AEs (n)	28	13	6
Hematologic AEs
Neutropenia (%)	18(32)	7(28)	1(5)
Leukopenia (%)	14(25)	5(20)	1(5)
Thrombocytopenia (%)	2(4)	1(4)	4(18)
Anemia (%)	8(14)	7(28)	2(9)
Receipt of growth factors	12(21)	5(20)	2(9)
Febrile neutropenia	1(2)	1(4)	1(5)
Nonhematologic AEs a
Peripheral neuropathy (%)	7(13)	4(16)	0(0)
Fatigue (%)	5(9)	4(16)	1(5)

^a Nonhematologic adverse events with incidence greater than 5%. Abbreviations: AEs, adverse events.